Alumis (ALMS) and Acelyrin (SLRN) said Monday that they agreed on an amended merger deal that reflects an increased share consideration for each Acelyrin share.
Under the amended agreement, Acelyrin shareholders will receive 0.4814 of an Alumis common share for each Acelyrin common share held, according to the statement. The companies said this represents a "meaningful increase" over the initial agreement.
The new deal terms will give Alumis shareholders a 52% stake in the merged company, while Acelyrin shareholders will own the remaining 48% stake, according to the companies.
Shareholders who own about 62% of Alumis's voting stock and Acelyrin shareholders who own about a 24% interest in the company have signed voting agreements to support the transaction, according to the statement. The companies are set to hold special meetings in May to seek shareholder approval for the merger.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.